

## **BioMarin to Present at the Wells Fargo Healthcare Conference**

PRNewswire-FirstCall

NOVATO, Calif.

BioMarin Pharmaceutical Inc. today announced that Jeffrey Cooper, Chief Financial Officer of BioMarin, will present a company update at the Wells Fargo Healthcare Conference in Boston on Thursday, June 24, 2010 at 2:30 p.m. ET.

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, [www.BMRN.com](http://www.BMRN.com). A replay of the call will be archived on the site for one week following the call.

### About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse(TM) (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Other product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in clinical development for the treatment of MPS IVA; PEG-PAL (PEGylated recombinant phenylalanine

ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU and BMN 195, which is currently in Phase I clinical development for the treatment of Duchenne Muscular Dystrophy. For additional information, please visit [www.BMRN.com](http://www.BMRN.com). Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme® and Kuvan® are registered trademarks of BioMarin Pharmaceutical Inc.

Firdapse(TM) is a trademark of BioMarin Huxley Ltd.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.

Contacts:

Investors

Eugenia Shen  
BioMarin Pharmaceutical Inc.  
(415) 506-6570

Media

Susan Berg  
BioMarin Pharmaceutical Inc.  
(415) 506-6594

First Call Analyst:

FCMN Contact: [eshen@bmrn.com](mailto:eshen@bmrn.com)

SOURCE: BioMarin Pharmaceutical Inc.

CONTACT: Investors, Eugenia Shen, +1-415-506-6570, or Media, Susan Berg, +1-415-506-6594, both of BioMarin Pharmaceutical Inc.

Web Site: <http://www.bmrn.com/>

---

<https://investors.biomin.com/2010-06-17-BioMarin-to-Present-at-the-Wells-Fargo-Healthcare-Conference>